Filing summary: Sigma Labs, Inc. — fiscal year ended December 31, 2013
Entity and period: The supplied filing is Sigma Labs, Inc.’s 2013 Form 10-K, not a filing for Nexttrip, Inc. It reports the year ended December 31, 2013, with 2012 comparisons. The filing describes an early-stage manufacturing-technology business, principally developing real-time quality-assurance products for additive manufacturing, alongside engineering consulting and licensing.
Financial performance and position
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | $1,071,439 | $986,499 |
| Cost of service revenue | $488,627 | $554,828 |
| Gross profit / gross margin | $582,812 / 54.4% | $431,671 / 43.8% |
| Net loss | $(734,117) | $(685,566) |
| Cash used in operations | $(311,299) | $(481,924) |
| Cash at year-end | $992,448 | $150,071 |
| Working capital | $1,180,973 | $315,574 |
| Total liabilities | $141,161 | $133,942 |
Revenue increased about 8.6%, while gross profit rose about 35.0% as service costs declined. Gross margin improved by roughly 10.6 percentage points. The net loss widened about 7.1%, reflecting higher general and administrative and stock-compensation expenses, plus an $87,340 impairment of intangible assets. There was no interest expense in 2013 and no income-tax expense. Basic and diluted loss per share were each reported as $(0.00), rounded.
Cash from financing activities was $1,180,833 in 2013, primarily reflecting stock financing; investing activities used $27,157. The filing reports no credit facilities and no material debt. Year-end current assets were $1,322,134 and current liabilities $141,161. The company reported a working-capital surplus, but remained loss-making and dependent on external funding and customer receipts.
Changes, outlook, and risks
- Revenue mix and customer concentration: Revenue remained primarily consulting-based; 2013 also included $109,096 from PrintRite3D system sales and $25,000 in Allotrope license fees. Three customers represented 50%, 22%, and 19% of revenue, respectively.
- Funding and dilution: In January 2014, the company sold 43.75 million shares for $3.5 million gross proceeds and issued a warrant for up to 14,259,259 shares at $0.15. Management reported net proceeds of $3.301 million after offering costs. Further equity or debt financing may be needed and could dilute existing holders.
- Management outlook: Management expected continued development and possible commercialization of IPQA/PrintRite3D in 2014–2015. As of March 31, 2014, it cited two active B6 Sigma consulting contracts expected to generate up to approximately $266,000 in 2014. It believed available funds and anticipated receipts could cover 2014 operating expenses, but noted continued funding depended on consulting revenue and securities sales. No quantified sales or profit guidance was provided.
- Commercialization uncertainty: Product offerings were at beta or development stage; successful market adoption, licensing, and partnerships were not assured. The company had only three full-time and one part-time employee as of March 31, 2014.
- Going concern: The auditor’s report and the filing state that recurring losses and lack of profitable operations raise substantial doubt about the company’s ability to continue as a going concern. The audit opinion was unqualified, but the financial statements contain no adjustments for the outcome of this uncertainty.
- Other notable risks: Fixed-price contract cost overruns, government-contract audit and termination exposure, dependence on key personnel, intellectual-property protection and competition, and thin, sporadic OTC trading. Management reported disclosure controls and internal control over financial reporting effective at year-end; the auditor did not attest to internal-control effectiveness.
- Unusual items and corporate actions: The $87,340 impairment related to Sumner customer-contact intangibles as the company planned to stop servicing those contracts. Management decided in March 2014 to discontinue Sumner contracts and planned to dissolve Sumner during 2014. No legal proceedings were reported as pending.
Important facts for investors to verify
- Confirm the issuer identity: this text is Sigma Labs, Inc., not Nexttrip, Inc.; verify whether the intended filing was different.
- Review the full audited financial statements and notes, especially cash runway, the going-concern disclosure, and the January 2014 financing terms and net proceeds.
- Assess whether concentrated consulting revenue can be sustained and whether the stated 2014 contract opportunities converted to recognized revenue and cash collections.
- Verify commercialization progress, customer adoption, and economics for PrintRite3D/IPQA, rather than relying on management’s prospective statements.
- Check subsequent share issuance, warrant exercises, and other potential dilution against the reported March 31, 2014 share count.